ArticleCureus2026
Entecavir-Induced Lichenoid Drug Eruption: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Entecavir is a highly potent antiviral medication used in the treatment of chronic hepatitis B infection and has demonstrated an excellent safety profile in clinical practice. Cutaneous adverse reactions to entecavir are exceedingly rare, with only seven cases reported in the literature to our knowledge. Here, we report the case of an adult female receiving entecavir therapy for chronic hepatitis B who developed a lichenoid drug eruption secondary to the medication. The rash resolved promptly following drug discontinuation and supportive treatment. Various cutaneous morphological patterns associated with entecavir have been reported in the literature, including immediate hypersensitivity reactions, maculopapular rash, granulomatous eruptions, erythematous plaques, bullous fixed drug eruption, and lichenoid erythematous patches. Clinicians should remain aware of the potential for cutaneous adverse drug reactions associated with entecavir and their varied morphological presentations to facilitate prompt recognition and appropriate management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.